No data to show
XCNQ
PREV
Market cap14mUSD
Aug 08, Last price
0.04CAD
1D
0.00%
1Q
0.00%
IPO
-55.13%
Name
Preveceutical Medical Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.92%
Rev. gr., 5y
-12.64%
Revenues
0k
Net income
-1m
L-13.97%
CFO
-297k
L+33.39%
Profile
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 629 | 472 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (629) | (472) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (1) | |||||||
Tax Rate | ||||||||
NOPAT | (629) | (472) | ||||||
Net income | (1,274) -13.97% | (1,481) -14.20% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (6) | |||||||
BB yield | 0.05% | |||||||
| Debt | ||||||||
Debt current | 3,834 | 3,232 | ||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 3,833 | 3,226 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (297) | (223) | ||||||
CAPEX | 4 | |||||||
Cash from investing activities | 850 | |||||||
Cash from financing activities | 294 | 212 | ||||||
FCF | (96) | (195) | ||||||
| Balance | ||||||||
Cash | 1 | 6 | ||||||
Long term investments | ||||||||
Excess cash | 1 | 6 | ||||||
Stockholders' equity | (5,778) | (4,635) | ||||||
Invested Capital | 3,834 | 3,232 | ||||||
ROIC | ||||||||
ROCE | 32.34% | 33.62% | ||||||
| EV | ||||||||
Common stock shares outstanding | 535,303 | 521,790 | ||||||
Price | 0.03 0.00% | 0.03 0.00% | ||||||
Market cap | 13,383 2.59% | 13,045 2.72% | ||||||
EV | 17,215 | 16,271 | ||||||
EBITDA | (619) | (462) | ||||||
EV/EBITDA | ||||||||
Interest | 310 | 237 | ||||||
Interest/NOPBT | ||||||||